Skip to main content
BioCentury on BioBusiness
Feature Story

Debating drug pricing

PhRMA, BIO, AHIP, National Coalition on Health Care debate drug pricing

By Steve Usdin, Washington Editor

Payers and politicians are waving the cost of Gilead Sciences Inc.'s Sovaldi sofosbuvir like a bloody shirt, claiming it is inflicting intolerable injury to the healthcare system. They are also using it to rally public indignation against future costly specialty drugs. The biopharma industry is just starting to mount a defense that rests on the value of a cure to a deadly disease and the corrosive effects on innovation of implications that drug prices should reflect the incremental cost to develop a specific product.

An interview with representatives of both stakeholder groups broadcast on BioCentury This Week on July 13 highlighted the need for collaboration, as well as the size of the divide that must be bridged, to arrive at solutions. National Coalition on Health Care President and CEO John Rother and America's Health Insurance Plans spokesperson Brendan Buck said if all specialty drugs are priced like Sovaldi, they will soon break the bank.

Full Article

200th Show

  • COVER STORY

    Fixing mitophagy in Parkinson's disease

    Genentech has pulled back the curtain on its efforts in Parkinson's disease and described a new and potentially disease-modifying target involved in the clearance of damaged mitochondria. The Roche unit now needs to determine whether the deubiquitinase -- USP30 -- is indeed druggable.

  • TRANSLATIONAL NOTES

    Partnering in pediatrics

    Rare pediatric diseases are getting a boost from Alexion Pharmaceuticals, who recently announced a research collaboration with Cincinnati Children's Hospital Medical Center.

  • TARGETS & MECHANISMS

    New route for old cancer agents

    Researchers at the University of Wisconsin-Madison and Cellectar Biosciences have improved the safety of broad-spectrum cytotoxic drugs by engineering molecules that specifically target malignant cells. The key was exploiting differences in lipid architecture between the two types of cells.

  • Hedgehog joins the resistance

    Hedgehog-mediated degradation of chemotherapeutics is a key resistance mechanism in AML, according to findings from Canadian researchers. Their next step is clinical testing of a chemotherapy-hedgehog antagonist combination.

  • THERAPEUTICS

    This Week in Therapeutics

    Stabilizing PLA2G5 or inhibiting PLA2G2E to treat obesity; using NOGO-A inhibitors and then physical therapy to improve motor recovery after stroke; antagonizing ABL1 to block neovascularization in retinopathy; and more...

  • TECHNIQUES

    This Week in Techniques

    Predicting epidemic variants of mosquito-borne RNA viruses using an in vivo infection system; inducing broadly neutralizing antibodies with an influenza A virus hemagglutinin stem fragment; monitoring miR-1202 expression to predict antidepressant treatment response; and more...

Subscribe Now
Free Trial